Xiaoxi Xu, Satya Pathi, Limei Shang, Yan Liu, Peng Han, Likun Zhang, Wenqing Yang, Binchen Mao, Davy Ouyang, Henry Li
Patient-derived cancer organoids (PDO) are a new and innovative preclinical oncology model system. PDOs are a comprehensive 3D spheroid culture that harbor cancer multicellular components, mimicking cancer lesion structures and tumor heterogeneity.
PDX-derived cancer organoids (PDXO) are also being developed from patient-derived xenograft (PDX) models. PDXOs can be used as scalable and high throughput compatible drug screening platforms.
We are establishing PDXOs from our large collection of genomically and phenotypically annotated and validated PDX models. This poster details the first phase of PDXO development from CRC, lung, gastric, and head and neck PDX, featuring model characterization, QC, and initial SoC assessment.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-27
landing_page
PDX/Databases